Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A2TSL71
Tue, 17.09.2024
SYNLAB AG
Cinven to sell minority stake in SYNLAB to strategic investor Labcorp
International private equity firm, Cinven, has reached an agreement to sell an indirect minority stake in SYNLAB, a leader in medical diagnostic services and specialty testing in Europe, to strategic investor Labcorp. Labcorp is a global leader of innovative and comprehensive la [ … ]
Tue, 17.09.2024
SYNLAB AG
Cinven to sell minority stake in SYNLAB to strategic investor Labcorp
International private equity firm, Cinven, has reached an agreement to sell an indirect minority stake in SYNLAB, a leader in medical diagnostic services and specialty testing in Europe, to strategic investor Labcorp. Labcorp is a global leader of innovative and comprehensive la [ … ]
Tue, 04.06.2024
SYNLAB AG
Cybersecurity Incident at Synnovis in UK
SYNLAB AG ("SYNLAB", FSE: SYAB) confirms that Synnovis, a partnership between two London-based hospital Trusts and SYNLAB UK & Ireland, was the victim of a cyber-attack on 3 June 2024.
A taskforce of IT experts from Synnovis and the National Health Service in UK (NHS England) is working diligently to fu [ … ]
Wed, 08.05.2024
SYNLAB AG
SYNLAB delivers strong performance in Q1 2024
Revenue at €682 million
Strong underlying organic growth at 3.9% (Q1 2023: 10.0%); 5.2% adjusted for working days
Adjusted EBITDA at €123 million (increased by 4% compared to Q1 2023)
Strong Adjusted EBITDA margin at 18.0% (Q1 2023: 16.9%), at the upper end of the guided range for FY 2024 of 17-1 [ … ]
Wed, 08.05.2024
SYNLAB AG
SYNLAB delivers strong performance in Q1 2024
Revenue at €682 million
Strong underlying organic growth at 3.9% (Q1 2023: 10.0%); 5.2% adjusted for working days
Adjusted EBITDA at €123 million (increased by 4% compared to Q1 2023)
Strong Adjusted EBITDA margin at 18.0% (Q1 2023: 16.9%), at the upper end of the guided range for FY 2024 of 17-1 [ … ]
Tue, 30.04.2024
SYNLAB AG
SYNLAB Italy has restored operations after cyber-attack
SYNLAB Italy has restored operations and will gradually resume all services for patients and customers.
Due to a cyber-attack, SYNLAB had suspended operations in Italy as a precautionary measure.
SYNLAB Group confirms no impact on operations in other countries.
SYNLAB AG ("SYNLAB", FSE [ … ]
Mon, 25.03.2024
SYNLAB AG
Revenue at €2.64 billion
Strong underlying organic growth: 6.4% (Q4 2023: 4.9%), well above the mid-term organic growth target
Adjusted EBITDA margin at 16.6% (Q4 2023: 17.0%)
€40 million of SALIX savings
Unlevered free cash flow at €75 million
Eight acquisitions completed with an EV of €90 million
Active portfolio management strategy impro [ … ]
Mon, 25.03.2024
SYNLAB AG
Revenue at €2.64 billion
Strong underlying organic growth: 6.4% (Q4 2023: 4.9%), well above the mid-term organic growth target
Adjusted EBITDA margin at 16.6% (Q4 2023: 17.0%)
€40 million of SALIX savings
Unlevered free cash flow at €75 million
Eight acquisitions completed with an EV of €90 million
Active portfolio management strategy impro [ … ]
Wed, 08.11.2023
SYNLAB AG
SYNLAB AG: Continued strong performance in the third quarter of 2023
Robust 9M 2023 performance with revenue of €2.0 billion
Strong underlying organic growth: 6.9% in 9M 2023 (Q3 2023: 5.1%), well above the mid-term organic growth target
Adjusted EBITDA margin in 9M 2023 at 16.5% (Q3 2023: 15.6%), in line with the seasonality of the SYNLAB busine [ … ]
Thu, 02.11.2023
SYNLAB AG
SYNLAB AG publishes Joint Reasoned Statement on public acquisition offer by Cinven
Management Board and Supervisory Board of SYNLAB AG published their Joint Reasoned Statement, in which they make a neutral statement. The Boards abstain from a recommendation to the SYNLAB Shareholders whether to accept or decline the Offer.
The Management Board [ … ]